Article
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.
Urologic oncology - 1 Feb 2013
Liu Glenn, Chen Yu-Hui, Kolesar Jill, Huang Wei, Dipaola Robert, Pins Michael, Carducci Michael, Stein Mark, Bubley Glenn J, Wilding George
Abstract excerpt
PURPOSE: Activation of the epidermal growth factor pathway is important in prostate cancer development and the transcription of androgen receptor regulated genes. This study evaluated the potential activity of lapatinib in men with biochemically-relapsed androgen-dependent (stage D0) prostate cancer. PATIENTS AND METHODS: Patients with a rising PSA after primary therapy for prostate cancer were enrolled. A PSA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
